Skip to main content

Table 1 Patients demographics and baseline characteristics

From: Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): a phase I clinical study

Patient

Sex

Age (years)

DM duration (years)

HbA1c

Eye

DME duration (years)

BVCA(logMar) baseline

IOP baseline (mmHg)

CSFT (μm) baseline

Lens Opacity Score

Laser PRP/ST

Anti-VEGF

IVTA

1

M

69

8.0

9.2

OS

4

1.30

11

479

2 + /4 + 

Yes

Beva

Yes

2

M

70

7.0

8.5

OS

3

1.10

15

587

1 + /4 + 

Yes

Beva

Yes

3

M

70

10.0

8.0

OS

2

0.40

13

612

1 + /4 + 

Yes

Beva

No

4

M

69

15.0

8.5

OD

2

0.40

17

514

1 + /4 + 

Yes

Beva

No

5

F

70

16.0

9.1

OD

3

1.10

16

583

1 + /4 + 

Yes

Beva

Yes

6

F

66

12.0

7.5

OS

3

0.70

16

586

1 + /4 + 

Yes

Beva

Yes

7

F

60

9.0

9.5

OS

2

0.40

17

393

1 + /4 + 

Yes

Beva

No

8

F

63

8.0

9.0

OD

2

0.40

16

387

1 + /4 + 

Yes

Beva

No

9

F

64

12.0

9.0

OS

2

0.30

16

356

1 + /4 + 

Yes

Beva

No

10

F

67

10.0

9.5

OD

2

0.30

12

306

1 + /4 + 

Yes

Beva

Yes

Mean

 

66.8

10.7

8.7

 

2, 3

0.64

14.9

480.3

1.1

   

SD

 

3.5

2.9

0.6

  

0.38

2.1

112.4

    
  1. DM diabetes mellitus, HbA1c
  2. Those values correspond to: mean and mean standart deviation of age (years), DM duration in years, HbA1c, DME duration in years, BCVA logMar, IOP (mmHg), CFST in μm and the mean of lens opacity score